News | November 11, 2022
IMPCL registers impressive threefold increase in profit for FY21-22
The dividend cheque of Rs. 9.93 crore for the Ministry of Ayush was handed over to Sonowal
The dividend cheque of Rs. 9.93 crore for the Ministry of Ayush was handed over to Sonowal
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
The policy aspires to reduce cost of logistics in India to be comparable to global benchmarks by 2030
India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved
The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
Subscribe To Our Newsletter & Stay Updated
